The importance of conservative measures in peripheral arterial disease: An update

Angiology

Volumn 59, Issue 5, 2008, Pages 529-533

  Paraskevas, Kosmas I ^a   Papas, Theofanis T ^a   Pavlidis, Polyvios ^a   Bessias, Nikolaos ^a   Andrikopoulos, Vassilios ^a  

^a RED CROSS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG MECHANISM; DYSLIPIDEMIA; EDITORIAL; EXERCISE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; PREVALENCE; PRIMARY MEDICAL CARE; PROPHYLAXIS; SMOKING HABIT; STROKE; SYSTEMATIC REVIEW;

ANGIOGENESIS INDUCING AGENTS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DISEASE PROGRESSION; DYSLIPIDEMIAS; EXERCISE; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; SMOKING; SMOKING CESSATION;

EID: 53949114831     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708318381     Document Type: Editorial

References (58)

1. Alzamora MT, Baena-Diez JM, Sorribes M., et al. Peripheral Arterial Disease study (PERART): prevalence and predictive values of asymptomatic peripheral arterial occlusive disease related to cardiovascular morbidity and mortality. BMC Public Health. 2007 ; 7: 348.
2. Shammas NW Epidemiology, classification and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007 ; 3: 229-234.
3. Sritara P., Sritara C., Woodward M., et al. Prevalence and risk factors of peripheral arterial disease in a selected Thai population. Angiology. 2007 ; 58: 572-578.
4. Centers for Disease Control and Prevention (CDC). Lower extremity disease among persons aged > or =40 years with and without diabetes-United States, 1992-2002. MMWR Morb Mortal Wkly Rep. 2005 ; 54: 1158-1160.
5. Ostchega Y., Paulose-Ram R., Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007 ; 55: 583-589.
6. Steinberg BA, Ballantyne CM, Bhatt DL, et al. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 ; 6: 72-75.
7. Doubeni CA, Yood RA, Emani S., Gurwitz JH Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. Angiology. 2006 ; 57: 171-180.
8. Lacroix P., Aboyans V., Voronin D., Le Guvader A., Cautres M., Lasker M. High prevalence of undiagnosed patients with peripheral arterial disease in patients hospitalised for non-vascular disorders. Int J Clin Pract. 2008 ; 62: 59-64.
9. Poredos P., Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007 ; 58: 309-315.
10. Paraskevas KI, Mikhailidis DP, Liapis CD Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology. 2007 ; 58: 329-335.
11. Hooi JD, Stoffers HE, Knotterus JA, Van Ree JW The prognosis of non-critical ischemia of population-based epidemiological evidence. Br J Gen Pract. 1999 ; 49: 49-55.
12. Nukumizu Y., Matsushita M., Sakurai T., Kobavashi M., Nishikimi N., Komori K. Comparison of Doppler and oscillometric ankle blood pressure measurement in patients with angiographically documented lower extremity arterial occlusive disease. Angiology. 2007 ; 58: 303-308.
13. Huegli RW, Aschwanden M., Bongartz G., et al. Intraarterial MR angiography and DSA in patients with peripheral arterial occlusive disease: prospective comparison. Radiology. 2006 ; 239: 901-908.
14. Bui TD, Gelfand D., Whipple S., et al. Comparison of CT and catheter arteriography for evaluation of peripheral arterial disease. Vasc Endovascular Surg. 2005 ; 39: 481-490.
15. Fleischmann D., Hallett RL, Rubin GD CT angiography of peripheral arterial disease. J Vasc Interv Radiol. 2006 ; 17: 3-26.
16. Janka R., Wenkel E., Fellner C., Lang W., Bautz W., Uder M. Magnetic resonance angiography of the peripheral vessels in patients with peripheral arterial occlusive disease: when is an additional conventional angiography required ? Cardiovasc Intervent Radiol. 2006 ; 29: 220-229.
17. Baumgartner I., Thoeny HC, Kummer O., et al. Leg ischemia: assessment with MR angiography and spectroscopy. Radiology. 2005 ; 234: 833-841.
18. Alnaeb ME, Crabtree VP, Boutin A., Mikhailidis DP, Seifalian AM, Hamilton G. Prospective assessment of lower-extremity peripheral arterial disease in diabetic patients using a novel automated optical device. Angiology. 2007 ; 58: 579-585.
19. Alnaeb ME, Alobaid N., Seifalian AM, et al. Optical techniques in the assessment of peripheral arterial disease. Curr Vasc Pharmacol. 2007 ; 5: 53-59.
20. Parameswaran GI, Brand K., Dolan J. Pulse oximetry as a potential screening tool for lower extremity arterial disease in asymptomatic patients with diabetes mellitus. Arch Intern Med. 2005 ; 165: 442-446.
21. Kakafika AI, Mikhailidis DP Smoking and aortic disease. Circ J. 2007 ; 71: 1173-1180.
22. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol. 2007 ; 5: 276-292.
23. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007 ; 58: 450-457.
24. Youssef F., Gupta P., Mikhailidis DP, et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology. 2005 ; 56: 279-287.
25. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004 ; 40: 1158-1165.
26. Giannini D., Leone A., Di Bisceglie D., et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilation in healthy individuals. Angiology. 2007 ; 58: 211-217.
27. Duprez DA Pharmacological interventions for peripheral artery disease. Expert Opin Pharmacother. 2007 ; 8: 1465-1477.
28. Robless P., Mikhailidis D., Stansby G. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 ; 1 :CD003748. doi: 10.1002/14651858.CD0037 48.pub3.
29. Crowther RG, Spinks WL, Leicht AS, Sangla K., Quiqley F., Golledge J. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease. J Vasc Surg. 2008 ; 47: 303-309.
30. McDermott MM, Liu K., Ferrucci L., et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med. 2006 ; 144: 10-20.
31. Gardner AW, Clancy RJ The relationship between ankle-brachial index and leisure-time physical activity in patients with intermittent claudication. Angiology. 2006 ; 57: 539-545.
32. Gardner AW, Phoelman ET Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA. 1995 ; 274: 975-980.
33. Gardner AW, Montgomery PS, Parker DE Physical activity is a predictor of all-cause mortality in patients with intermittent claudication. J Vasc Surg. 2008 ; 47: 117-122.
34. Garg PK, Tian L., Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation. 2006 ; 114: 242-248.
35. Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, et al. Lipid management and peripheral arterial disease. Curr Drug Targets. 2007 ; 8: 561-570.
36. Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007 ; 45: 936-943.
37. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007 ; 45: 645-654.
38. Alnaeb ME, Alobaid N., Seifalian AM, et al. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006 ; 20: 696-705.
39. Youssef F., Gupta P., Seifalian AM, Myint F., Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology. 2004 ; 55: 53-62.
40. Alnaeb ME, Youssef F., Mikhailidis DP, et al. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006 ; 57: 65-71.
41. Spring S., Simon R., van der Loo B., et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost. 2008 ; 99: 182-189.
42. Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005 ; 104: 264-268.
43. Paraskevas KI, Liapis CD, Hamilton G., et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery ? Eur J Vasc Endovasc Surg. 2006 ; 32: 286-293.
44. Poussa H., Strandberg TE, Tikkanen I., Kauhanen P., Lepantalo M. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral arterial disease. Scand Cardiovasc J. 2007 ; 41: 138-141.
45. Federman DG, Ranani DC, Kirsner RS, Bravata DM Lipid-lowering therapy in patients with peripheral arterial disease: are guidelines being met ? Mayo Clin Proc. 2005 ; 80: 494-498.
46. Robless PA, Okonko D., Lintott P., et al. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003 ; 25: 16-22.
47. Jagroop IA, Matsagas MI, Geroulakos G., Mikhailidis DP The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets. 2004 ; 15: 117-125.
48. Robless P., Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg. 2001 ; 88: 787-800.
49. Antithrombotic Trialists ' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86.
50. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 ; 348: 1329-1339.
51. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342: 145-153.
52. Mehler PS, Coll JR, Estacio R., et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003 ; 107: 753-756.
53. Andersen CA, Roukis TS The diabetic foot. Surg Clin North Am. 2007 ; 87: 1149-1177.
54. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853.
55. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352: 854-865.
56. Paraskevas KI, Mikhailidis DP Angiogenesis: a promising treatment option in patients with peripheral arterial disease. Curr Vasc Pharmacol. In press.
57. Mikroulis D., Papanas N., Maltezos E., Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol. 2007 ; 5: 195-209.
58. Jia L., Takahashi M., Yoshioka T., Morimoto H., Ikeda U. Therapeutic potential of endothelial progenitor cells for cardiovascular diseases. Curr Vasc Pharmacol. 2006 ; 4: 59-65.